Last reviewed · How we verify

placebo+chemotherapy — Competitive Intelligence Brief

placebo+chemotherapy (placebo+chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy enhancer. Area: Oncology.

phase 3 Chemotherapy enhancer Oncology Small molecule Live · refreshed every 30 min

Target snapshot

placebo+chemotherapy (placebo+chemotherapy) — Jiangsu HengRui Medicine Co., Ltd.. This drug works by enhancing the effects of chemotherapy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
placebo+chemotherapy TARGET placebo+chemotherapy Jiangsu HengRui Medicine Co., Ltd. phase 3 Chemotherapy enhancer

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy enhancer class)

  1. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo+chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: